Myriad Genetics (MYGN) Change in Accured Expenses (2009 - 2026)

Myriad Genetics (MYGN) has reported Change in Accured Expenses for 18 consecutive years, with -$7.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 40.32% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$22.5 million (up 42.01% YoY), while the FY2025 annual figure was -$27.5 million, up 32.93% from the prior year.
• Change in Accured Expenses slipped to -$7.4 million in Q1 2026 per MYGN's latest filing, from -$6.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $71.9 million in Q2 2023 and bottomed at -$59.4 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged -$7.9 million across 5 years, with a median of -$6.7 million in 2025.
• On a YoY basis, Change in Accured Expenses climbed as much as 4340.0% in 2023 and fell as far as 2021.43% in 2023.
• Myriad Genetics' Change in Accured Expenses stood at -$2.8 million in 2022, then slumped by 2021.43% to -$59.4 million in 2023, then jumped by 53.7% to -$27.5 million in 2024, then jumped by 75.64% to -$6.7 million in 2025, then fell by 10.45% to -$7.4 million in 2026.
• Business Quant data shows MYGN's Change in Accured Expenses at -$7.4 million in Q1 2026, -$6.7 million in Q4 2025, and $8.4 million in Q3 2025.